Interestingly, densitometric analysis showed no significant differences in VEGF-A levels in the early treatment phase, but a clear and significant increase following Regorafenib treatment during tumor progression, indicating a compensatory upregulation of VEGF-A upon Regorafenib treatment which might contribute to its lack of efficacy on angiogenesis (Supplementary Fig. S7C–F). This evidence concerns the gene VEGFA and neoplasm.